Posted by Michael Wonder on 20 Jul 2021
FDA approves Octapharma’s Octagam 10% for adult dermatomyositis
20 July 2021 - FDA approval based on positive results of international, multi-center ProDERM study.
The U.S. FDA has granted approval to Octapharma USA for Octagam 10% [immunoglobulin intravenous (human)], the first and only intravenous immunoglobulin to be indicated for the treatment of adult dermatomyositis, a rare immune mediated inflammatory disease.
